NASDAQ:AGEN
Agenus Inc. Stock News
$6.50
-1.65 (-20.25%)
At Close: Apr 15, 2024
Agenus New Trials Set It Up For The Long Haul
12:07pm, Tuesday, 27'th Sep 2022
Agenus stock is way down post being edged out in PD1 therapy in 2021. The company recently started trials in colorectal cancer and melanoma.
Is Trending Stock Agenus Inc. (AGEN) a Buy Now?
10:32am, Monday, 19'th Sep 2022
Agenus (AGEN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
7 Penny Stocks That Actually Have a Buy Rating
06:00am, Monday, 19'th Sep 2022
Finding penny stocks with buy ratings is becoming increasingly difficult. The higher interest rates go, the more risk-averse the markets become.
Is Most-Watched Stock Agenus Inc. (AGEN) Worth Betting on Now?
10:32am, Tuesday, 06'th Sep 2022
Recently, Zacks.com users have been paying close attention to Agenus (AGEN). This makes it worthwhile to examine what the stock has in store.
Agenus Inc. (AGEN) CEO Garo Armen on Q2 2022 Results - Earnings Call Transcript
10:19am, Tuesday, 09'th Aug 2022
Agenus Inc. (NASDAQ:AGEN ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Ethan Lovell - Chief of External Affairs & Communications Officer Garo Armen - Chairman & Chi
Why Shares of Agenus Inc. Rose 10.1% on Tuesday
05:42pm, Tuesday, 26'th Jul 2022
The company has a promising colon cancer therapy.
3 Amazing Stocks Under $10
06:30am, Sunday, 10'th Jul 2022
Here's why we like SeaSpine, Recursion Pharmaceuticals, and Agenus.
Why Did Agenus Stock Jump In June; What Is The Outlook?
09:30am, Wednesday, 06'th Jul 2022
We highlight the promising aspects of the AGEN story. We touch upon certain catalysts in the foreseeable future.
Why Agenus Stock Is Soaring Today
11:14am, Wednesday, 29'th Jun 2022
The company reported encouraging results from an early study of its experimental colorectal cancer combo therapy.
Agenus Touts 'Unprecedented Activity' For Botensilimab/Balstilimab Combo In Colorectal Cancer
08:44am, Wednesday, 29'th Jun 2022
Agenus Inc (NASDAQ: AGEN) has announced expanded data from the Phase 1b study of botensilimab and balstilimab in patients with microsatellite stable colorectal cancer. The data demonstrate that the
Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress
08:30am, Tuesday, 21'st Jun 2022
LEXINGTON, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and
Agenus Announces Virtual Annual Shareholders Meeting
08:30am, Wednesday, 25'th May 2022
LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and
3 Biotech Stocks With a Cash Pile Higher Than Their Valuations
08:00am, Saturday, 21'st May 2022
Our roundtable found three biotechs with a nice cash cushion.
Agenus (AGEN) Q1 2022 Earnings Call Transcript
12:01am, Wednesday, 11'th May 2022 The Motley Fool
AGEN earnings call for the period ending March 31, 2022.
Agenus Inc. (AGEN) CEO Garo Armen on Q1 2022 Results - Earnings Call Transcript
03:44pm, Tuesday, 10'th May 2022
Agenus Inc. (NASDAQ:AGEN ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Christine Klaskin - Vice President of Finance, Principal Financial Officer & Principal Accountin
